Logo

454 CEO Lands at Ensemble as CuraGen CEO Steps Down

Apr 06, 2005

NEW YORK, April 6 (GenomeWeb News) - CuraGen, the parent company of 454 Life Sciences, this week said that CEO Jonathan Rothberg will be stepping down.

 

In a separate announcement, Ensemble Discovery said it has hired former 454 president and CEO Richard Begley as its new president and CEO.

 

New Haven, Conn.-based CuraGen said it has begun to look for a new CEO, and that Rothberg will remain in his position until a replacement is appointed. Rothberg has been the chairman and CEO of the pharmaceutical company since it was founded seven years ago.

 

According to CuraGen, Patrick Zenner, a member of the board of directors, has been asked to chair the search committee for the new CEO, and Rothberg said in a statement that he would assist in the search.

Breaking News
The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.